Cargando…

Dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy

BACKGROUND: MDC1A is a congenital neuromuscular disorder with developmentally complex and progressive pathologies that results from a deficiency in the protein laminin α(2). MDC1A is associated with a multitude of pathologies, including increased apoptosis, inflammation and fibrosis. In order to ass...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mehuron, Thomas, Kumar, Ajay, Duarte, Lina, Yamauchi, Jenny, Accorsi, Anthony, Girgenrath, Mahasweta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4114446/ https://www.ncbi.nlm.nih.gov/pubmed/25075272 http://dx.doi.org/10.1186/2044-5040-4-14

Ejemplares similares

Correction: dysregulation of matricellular proteins is an early signature of pathology in laminin-deficient muscular dystrophy
por: Mehuron, Thomas, et al.
Publicado: (2014)

Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A)
por: Vohra, Ravneet, et al.
Publicado: (2015)

Fibrogenesis in LAMA2-Related Muscular Dystrophy Is a Central Tenet of Disease Etiology
por: Accorsi, Anthony, et al.
Publicado: (2020)

Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy
por: Willmann, Raffaella, et al.
Publicado: (2017)

Diseased muscles that lack dystrophin or laminin-α2 have altered compositions and proliferation of mononuclear cell populations
por: Girgenrath, Mahasweta, et al.
Publicado: (2005)

Linker molecules between laminins and dystroglycan ameliorate laminin-α2–deficient muscular dystrophy at all disease stages
por: Meinen, Sarina, et al.
Publicado: (2007)

Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy
por: Nguyen, Quynh, et al.
Publicado: (2019)

Antioxidants Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Harandi, Vahid M., et al.
Publicado: (2020)

miR-410 and miR-495 Are Dynamically Regulated in Diverse Cardiomyopathies and Their Inhibition Attenuates Pathological Hypertrophy
por: Clark, Amanda L., et al.
Publicado: (2016)

Long-term follow-up of laminin α2 (merosin)-deficient muscular dystrophy in a cat
por: Awamura, Yuichi, et al.
Publicado: (2008)

Bortezomib Does Not Reduce Muscular Dystrophy in the dy(2J)/dy(2J) Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy
por: Körner, Zandra, et al.
Publicado: (2016)

Immobilization of Dystrophin and Laminin α2-Chain Deficient Zebrafish Larvae In Vivo Prevents the Development of Muscular Dystrophy
por: Li, Mei, et al.
Publicado: (2015)

Laminin α2 Deficiency-Related Muscular Dystrophy Mimicking Emery-Dreifuss and Collagen VI related Diseases
por: Nelson, Isabelle, et al.
Publicado: (2015)

Laminin and Integrin in LAMA2-Related Congenital Muscular Dystrophy: From Disease to Therapeutics
por: Barraza-Flores, Pamela, et al.
Publicado: (2020)

Natural disease history of the dy(2J) mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy
por: Pasteuning-Vuhman, S., et al.
Publicado: (2018)

Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A)
por: Meinen, Sarina, et al.
Publicado: (2012)

Early skeletal muscle pathology and disease progress in the dy(3K)/dy(3K) mouse model of congenital muscular dystrophy with laminin α2 chain-deficiency
por: Gawlik, Kinga I., et al.
Publicado: (2019)

Mutation-independent Proteomic Signatures of Pathological Progression in Murine Models of Duchenne Muscular Dystrophy
por: van Westering, Tirsa L. E., et al.
Publicado: (2020)

Matricellular CCN proteins
por: Perbal, Bernard
Publicado: (2008)

Matricellular proteins: an overview
por: Bornstein, Paul
Publicado: (2009)

Revisiting the matricellular concept
por: Murphy-Ullrich, Joanne E., et al.
Publicado: (2014)

Potent pro-inflammatory and pro-fibrotic molecules, osteopontin and galectin-3, are not major disease modulators of laminin α2 chain-deficient muscular dystrophy
por: Gawlik, Kinga I., et al.
Publicado: (2017)

An atypical expression of core α-Dystroglycan and Laminin-α2 in skin fibroblasts of patients with congenital muscular dystrophies
por: Sabry, Sahar, et al.
Publicado: (2023)

A Splice Site Mutation in Laminin-α2 Results in a Severe Muscular Dystrophy and Growth Abnormalities in Zebrafish
por: Gupta, Vandana A., et al.
Publicado: (2012)

Progressive Muscular Dystrophy in α-Sarcoglycan–deficient Mice
por: Duclos, Franck, et al.
Publicado: (1998)

Molecular Signatures of Membrane Protein Complexes Underlying Muscular Dystrophy
por: Turk, Rolf, et al.
Publicado: (2016)

Deletion of exon 4 in LAMA2 is the most frequent mutation in Chinese patients with laminin α2-related muscular dystrophy
por: Ge, Lin, et al.
Publicado: (2018)

Characterization of Matricellular Protein Expression Signatures in Mechanistically Diverse Mouse Models of Kidney Injury
por: Feng, Daniel, et al.
Publicado: (2019)

Satellite cell contribution to disease pathology in Duchenne muscular dystrophy
por: Kodippili, Kasun, et al.
Publicado: (2023)

SPARC: a matricellular regulator of tumorigenesis
por: Arnold, Shanna A., et al.
Publicado: (2009)

Matricellular proteins in cutaneous wound healing
por: Cárdenas-León, Claudia Griselda, et al.
Publicado: (2022)

uPA deficiency exacerbates muscular dystrophy in MDX mice
por: Suelves, Mònica, et al.
Publicado: (2007)

uPA deficiency exacerbates muscular dystrophy in MDX mice
por: Suelves, Mònica, et al.
Publicado: (2007)

New aspects on patients affected by dysferlin deficient muscular dystrophy
por: Klinge, Lars, et al.
Publicado: (2009)

Effects of rituximab in two patients with dysferlin-deficient muscular dystrophy
por: Lerario, Alberto, et al.
Publicado: (2010)

Glycogenin-1 deficiency mimicking limb-girdle muscular dystrophy
por: Lefeuvre, Claire, et al.
Publicado: (2020)

Anesthetic Care of a Child With Merosin-Deficient Muscular Dystrophy
por: Munlemvo, Dolly M., et al.
Publicado: (2020)

Metabogenic and Nutriceutical Approaches to Address Energy Dysregulation and Skeletal Muscle Wasting in Duchenne Muscular Dystrophy
por: Rybalka, Emma, et al.
Publicado: (2015)

Dysregulated mechanisms underlying Duchenne muscular dystrophy from co-expression network preservation analysis
por: Mukund, Kavitha, et al.
Publicado: (2015)

A matricellular protein fibulin-4 is essential for the activation of lysyl oxidase
por: Noda, Kazuo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_242am9qggdnbadidgpbo1t8dko